Neurosense Therapeutics Ltd (NRSN) has a current Price-to-Book (P/B) ratio of -36.97. Compared to its 3-year average P/B ratio of -15.96, the current P/B ratio is approximately 131.58% higher. Relative to its 5-year average P/B ratio of -10.37, the current P/B ratio is about 256.53% higher. Neurosense Therapeutics Ltd (NRSN) has a Forward Free Cash Flow (FCF) yield of approximately -42.96%. Compared to its 3-year average FCF yield of -27.02%, the current FCF yield is approximately 59.01% lower. Relative to its 5-year average FCF yield of -22.37%, the current FCF yield is about 92.04% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for NRSN competitors is 11.45, providing a benchmark for relative valuation. Neurosense Therapeutics Ltd Corp (NRSN.O) exhibits a P/S ratio of 54.71, which is 377.67% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of NRSN increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of NRSN in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is NRSN currently overvalued or undervalued?

What is Neurosense Therapeutics Ltd (NRSN) fair value?

NRSN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Neurosense Therapeutics Ltd (NRSN) is between 0.09 to 1.47 according to relative valuation method.

How does NRSN's valuation metrics compare to the industry average?

The average P/S ratio for NRSN's competitors is 11.45, providing a benchmark for relative valuation. Neurosense Therapeutics Ltd Corp (NRSN) exhibits a P/S ratio of 54.71, which is 377.67% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Neurosense Therapeutics Ltd (NRSN) as of Mar 04 2026?

As of Mar 04 2026, Neurosense Therapeutics Ltd (NRSN) has a P/B ratio of -36.97. This indicates that the market values NRSN at -36.97 times its book value.

What is the current FCF Yield for Neurosense Therapeutics Ltd (NRSN) as of Mar 04 2026?

As of Mar 04 2026, Neurosense Therapeutics Ltd (NRSN) has a FCF Yield of -42.96%. This means that for every dollar of Neurosense Therapeutics Ltd's market capitalization, the company generates -42.96 cents in free cash flow.

What is the current Forward P/E ratio for Neurosense Therapeutics Ltd (NRSN) as of Mar 04 2026?

As of Mar 04 2026, Neurosense Therapeutics Ltd (NRSN) has a Forward P/E ratio of -2.54. This means the market is willing to pay $-2.54 for every dollar of Neurosense Therapeutics Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Neurosense Therapeutics Ltd (NRSN) as of Mar 04 2026?

As of Mar 04 2026, Neurosense Therapeutics Ltd (NRSN) has a Forward P/S ratio of 54.71. This means the market is valuing NRSN at $54.71 for every dollar of expected revenue over the next 12 months.

NRSN Valuation